デフォルト表紙
市場調査レポート
商品コード
1602214

ワクチン市場:タイプ別、技術タイプ別、投与経路別、適応症別、年齢層別-2025年~2030年の世界予測

Vaccines Market by Type (Monovalent Vaccine, Multivalent Vaccine), Technology Type (Inactivated Vaccines, Live-Attenuated Vaccines, Messenger RNA (mRNA) Vaccines), Route of administration, Indication, Age Group - Global Forecast 2025-2030


出版日
発行
360iResearch
ページ情報
英文 182 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.30円
ワクチン市場:タイプ別、技術タイプ別、投与経路別、適応症別、年齢層別-2025年~2030年の世界予測
出版日: 2024年10月31日
発行: 360iResearch
ページ情報: 英文 182 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ワクチン市場は、2023年に689億2,000万米ドルと評価され、2024年には741億6,000万米ドルに達すると予測され、CAGR 7.70%で成長し、2030年には1,158億9,000万米ドルに達すると予測されています。

ワクチンは、特定の疾患に対する免疫を提供する生物学的製剤であり、予防ヘルスケアにおいて重要です。ワクチン市場には、疾病予防のための予防用ワクチンや疾病治療のための治療用ワクチンなど、幅広い分野が含まれます。ワクチンの必要性は、mRNAワクチンのような新しいワクチン技術への需要を増加させ、COVID-19パンデミックのような世界の健康課題によって強調されています。最終用途は病院、診療所、研究機関などです。重要な成長要因は、世界の予防接種プログラムに対する意識の高まりと投資であり、政府や非政府組織によってさらに推進されています。技術の進歩は、研究開発資金の拡大と相まって、利害関係者にとってワクチン送達メカニズムや安定性の革新に有利な機会をもたらしています。しかし、厳しい規制政策、研究開発費の高騰、ワクチンへの躊躇といった課題は、市場の成長を阻害する可能性があります。さらに、発展途上国におけるサプライチェーンの混乱や不公平なアクセスは、大きな制約となります。技術革新や調査において有望な分野としては、個別化技術、アジュバント技術、針を使わない送達システムなどがあり、これらは有効性や患者のコンプライアンスを高める可能性があります。また、製薬会社、ハイテク企業、公衆衛生機関が協力することで、ブレークスルーを加速させることができることも示唆されています。ワクチン流通の効率化と結果追跡のためのデジタルヘルス・ソリューションの探求は、未開拓の可能性を示しています。競合情勢にもかかわらず、市場固有の拡大は、進化する治療ニーズと世界の公衆衛生の安全保障の必要性によって育まれています。全体として、ワクチン市場は、個別化免疫療法やサプライチェーンの透明性を高めるブロックチェーンのような新たな機会を活用する技術革新を活用しながら、入手しやすさと手頃な価格という課題に取り組むことを条件として、継続的な成長が期待されています。

主な市場の統計
基準年[2023] 689億2,000万米ドル
予測年[2024] 741億6,000万米ドル
予測年[2030] 1,158億9,000万米ドル
CAGR(%) 7.70%

市場力学:急速に進化するワクチン市場の主要市場インサイトを公開

ワクチン市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

  • 市場促進要因
    • 新たな感染症の流行とワクチン接種の利点に関する意識の高まり
    • ワクチン開発を奨励する政府資金の増加
  • 市場抑制要因
    • 高い開発コストと製品回収に関する問題
  • 市場機会
    • 革新的なワクチン開発のためのバイオテクノロジー企業による投資の急増
    • 官民間の協力関係の構築によるワクチン流通の改善
  • 市場の課題
    • ワクチンの承認プロセスの長さと、それに伴うワクチンの副作用

ポーターのファイブフォース:ワクチン市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析:ワクチン市場における外部からの影響の把握

外部マクロ環境要因は、ワクチン市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析ワクチン市場における競合情勢の把握

ワクチン市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスワクチン市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、ワクチン市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨ワクチン市場における成功への道筋を描く

ワクチン市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています:

1.市場の浸透度:現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度:新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化:最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報:競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション:将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています:

1.現在の市場規模と今後の成長予測は?

2.最高の投資機会を提供する製品、セグメント、地域はどこか?

3.市場を形成する主な技術動向と規制の影響とは?

4.主要ベンダーの市場シェアと競合ポジションは?

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か?

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 新たな感染症の蔓延とワクチン接種のメリットに関する認識の高まり
      • ワクチン開発を促進する政府資金の増額
    • 抑制要因
      • 開発コストの高騰と製品リコール問題
    • 機会
      • 革新的なワクチン開発に向けたバイオテクノロジー企業による投資の急増
      • 官民連携の台頭によりワクチンの配布が改善
    • 課題
      • 長期にわたるワクチン承認プロセスとそれに伴うワクチンの副作用
  • 市場セグメンテーション分析
    • タイプ:さまざまな株にさらされた場合に多価ワクチンが極めて重要
    • テクノロジータイプ:急速な発展と高い有効性により、mRNAワクチンの重要性が高まっています
    • 投与経路:免疫反応が強いため、筋肉内(IM)および皮下(SC)経路が好まれます。
    • 適応症:季節性インフルエンザの流行を予防するためのインフルエンザワクチンの普及
    • 年齢層:高齢者や慢性疾患を持つ人々に対する効果的なワクチン接種の必要性
  • ポーターのファイブフォース分析
  • PESTEL分析
    • 政治的
    • 経済
    • 社交
    • 技術的
    • 法律上
    • 環境

第6章 ワクチン市場:タイプ別

  • 一価ワクチン
  • 多価ワクチン

第7章 ワクチン市場:技術タイプ別

  • 無効化されたワクチン
  • ライブ減衰ワクチン
  • メッセンジャーRNA(mRNA)ワクチン
  • サブユニット、組み換え、多糖類、およびコンジュゲートワクチン
  • トキソイドワクチン
  • ウイルスベクターワクチン

第8章 ワクチン市場:投与経路別

  • 筋肉内および皮下
  • オーラル

第9章 ワクチン市場:適応症別

  • インフルエンザ菌b型
  • A型肝炎とB型肝炎
  • ヒトパピローマウイルス
  • 麻疹、おたふく風邪、風疹
  • 髄膜炎菌感染症
  • 肺炎球菌感染症
  • ポリオ
  • 狂犬病
  • ロタウイルス
  • 帯状疱疹
  • 破傷風、ジフテリア、百日咳
  • 水痘

第10章 ワクチン市場:年齢層別

  • 大人
  • 小児科

第11章 南北アメリカのワクチン市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第12章 アジア太平洋のワクチン市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第13章 欧州・中東・アフリカのワクチン市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第14章 競合情勢

  • 市場シェア分析、2023年
  • FPNVポジショニングマトリックス、2023年
  • 競合シナリオ分析
    • マンカインド・ファーマ、バーラト・セラムズとワクチンを20億米ドルで買収、ワクチン生産能力を拡大
    • サノフィとノババックスが提携し、新型COVID-19ワクチンの共同商品化とインフルエンザ・コロナ混合ワクチンの開発に着手
    • CureVacとMDアンダーソンが提携し、mRNAベースのがんワクチンを開発、高度ながん治療への道を開く
    • バーラト・バイオテックとビルトホーベン・バイオロジカルズがOPV生産強化で世界ポリオ撲滅活動強化へ提携
    • 武田薬品、デング熱ワクチンの世界のアクセス向上に向け提携、被害の大きい地域をターゲットに
    • アストラゼネカ、バイオテクノロジー企業イコサバックスを買収しワクチン能力を強化
    • インドのセラム研究所がCEPIと提携し、流行時の世界のワクチンのアクセスを向上
    • GSK、中国で帯状疱疹ワクチンShingrixを独占販売するためZhifeiと提携、公衆衛生とワクチンへのアクセス向上を目指す
    • ヤンセンとサノフィ、満たされていない医療ニーズに対応するワクチンプログラムの開発で協力
    • 世界の取り組みが、ジェノバ社の自己増幅mRNAワクチン(X型感染症に対する)への資金提供によりパンデミックへの備えを強化
    • バイエルン・ノルディックが米国でMpoxワクチンを発売、予防ヘルスケアと市場イノベーションを促進
  • 戦略分析と提言
    • アストラゼネカ
    • ファイザー株式会社
    • グラクソ・スミスクライン
    • メルク社
    • サノフィS.A.

企業一覧

  • Abbott Laboratories
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bavarian Nordic A/S
  • Bharat Biotech Ltd.
  • Biological E. Limited
  • BioNTech SE
  • Blue Lake Biotechnology
  • Capricor Therapeutics, Inc.
  • Chongqing Zhifei Biological Products Co., Ltd.
  • CSL Limited
  • CureVac N.V.
  • Daiichi Sankyo Company, Limited.
  • Emergent BioSolutions Inc.
  • Gennova Biopharmaceuticals Limited
  • GlaxoSmithKline PLC
  • Haffkine Bio-Pharmaceutical Corporation Ltd
  • Incepta Pharmaceuticals Ltd.
  • Inovio Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novavax, Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • Serum Institute of India Pvt. Ltd.
  • Sinovac Biotech Ltd.
  • Takeda Pharmaceutical Company Limited
  • VBI Vaccines Inc.
  • Versatope Therapeutics
  • Zydus Lifesciences Limited
図表

LIST OF FIGURES

  • FIGURE 1. VACCINES MARKET RESEARCH PROCESS
  • FIGURE 2. VACCINES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL VACCINES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL VACCINES MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL VACCINES MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL VACCINES MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL VACCINES MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL VACCINES MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL VACCINES MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES VACCINES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES VACCINES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. VACCINES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. VACCINES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. VACCINES MARKET DYNAMICS
  • TABLE 7. GLOBAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL VACCINES MARKET SIZE, BY MONOVALENT VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL VACCINES MARKET SIZE, BY MULTIVALENT VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL VACCINES MARKET SIZE, BY LIVE-ATTENUATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL VACCINES MARKET SIZE, BY MESSENGER RNA (MRNA) VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL VACCINES MARKET SIZE, BY SUBUNIT, RECOMBINANT, POLYSACCHARIDE, & CONJUGATE VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL VACCINES MARKET SIZE, BY TOXOID VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL VACCINES MARKET SIZE, BY VIRAL VECTOR VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL VACCINES MARKET SIZE, BY INTRAMUSCULAR & SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL VACCINES MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL VACCINES MARKET SIZE, BY HAEMOPHILUS INFLUENZAE TYPE B, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL VACCINES MARKET SIZE, BY HEPATITIS A & HEPATITIS B, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL VACCINES MARKET SIZE, BY HUMAN PAPILLOMAVIRUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL VACCINES MARKET SIZE, BY MEASLES, MUMPS, & RUBELLA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL VACCINES MARKET SIZE, BY MENINGOCOCCAL DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL VACCINES MARKET SIZE, BY PNEUMOCOCCAL DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL VACCINES MARKET SIZE, BY POLIO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL VACCINES MARKET SIZE, BY RABIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL VACCINES MARKET SIZE, BY ROTAVIRUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL VACCINES MARKET SIZE, BY SHINGLES/HERPES ZOSTER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL VACCINES MARKET SIZE, BY TETANUS, DIPHTHERIA, & PERTUSSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL VACCINES MARKET SIZE, BY VARICELLA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL VACCINES MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL VACCINES MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 61. MEXICO VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 74. AUSTRALIA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. AUSTRALIA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. AUSTRALIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. AUSTRALIA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. AUSTRALIA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 79. CHINA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. CHINA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. CHINA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. CHINA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. CHINA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 84. INDIA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. INDIA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. INDIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. INDIA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. INDIA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 89. INDONESIA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. INDONESIA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. INDONESIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. INDONESIA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. INDONESIA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 94. JAPAN VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. JAPAN VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. JAPAN VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. JAPAN VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 98. JAPAN VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 99. MALAYSIA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. MALAYSIA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. MALAYSIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. MALAYSIA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 103. MALAYSIA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 104. PHILIPPINES VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. PHILIPPINES VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. PHILIPPINES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. PHILIPPINES VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 108. PHILIPPINES VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 109. SINGAPORE VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. SINGAPORE VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. SINGAPORE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. SINGAPORE VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. SINGAPORE VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 114. SOUTH KOREA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. SOUTH KOREA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. SOUTH KOREA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. SOUTH KOREA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 118. SOUTH KOREA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 119. TAIWAN VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. TAIWAN VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. TAIWAN VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. TAIWAN VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 123. TAIWAN VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 124. THAILAND VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. THAILAND VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. THAILAND VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. THAILAND VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 128. THAILAND VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 129. VIETNAM VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. VIETNAM VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. VIETNAM VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. VIETNAM VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. VIETNAM VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 140. DENMARK VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. DENMARK VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. DENMARK VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. DENMARK VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 144. DENMARK VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 145. EGYPT VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. EGYPT VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. EGYPT VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 148. EGYPT VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 149. EGYPT VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 150. FINLAND VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. FINLAND VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. FINLAND VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 153. FINLAND VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 154. FINLAND VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 155. FRANCE VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. FRANCE VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. FRANCE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 158. FRANCE VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 159. FRANCE VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 160. GERMANY VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. GERMANY VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. GERMANY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 163. GERMANY VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 164. GERMANY VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 165. ISRAEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. ISRAEL VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. ISRAEL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 168. ISRAEL VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 169. ISRAEL VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 170. ITALY VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. ITALY VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. ITALY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 173. ITALY VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 174. ITALY VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 175. NETHERLANDS VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. NETHERLANDS VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. NETHERLANDS VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. NETHERLANDS VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 179. NETHERLANDS VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 180. NIGERIA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. NIGERIA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. NIGERIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 183. NIGERIA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 184. NIGERIA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 185. NORWAY VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. NORWAY VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. NORWAY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. NORWAY VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 189. NORWAY VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 190. POLAND VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. POLAND VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. POLAND VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 193. POLAND VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 194. POLAND VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 195. QATAR VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. QATAR VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. QATAR VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 198. QATAR VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 199. QATAR VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 200. RUSSIA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. RUSSIA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. RUSSIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 203. RUSSIA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 204. RUSSIA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 205. SAUDI ARABIA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. SAUDI ARABIA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. SAUDI ARABIA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 208. SAUDI ARABIA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 209. SAUDI ARABIA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 210. SOUTH AFRICA VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. SOUTH AFRICA VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. SOUTH AFRICA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 213. SOUTH AFRICA VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 214. SOUTH AFRICA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 215. SPAIN VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. SPAIN VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. SPAIN VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 218. SPAIN VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 219. SPAIN VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 220. SWEDEN VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. SWEDEN VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. SWEDEN VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 223. SWEDEN VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 224. SWEDEN VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 225. SWITZERLAND VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. SWITZERLAND VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. SWITZERLAND VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 228. SWITZERLAND VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 229. SWITZERLAND VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 230. TURKEY VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. TURKEY VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. TURKEY VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 233. TURKEY VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 234. TURKEY VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED ARAB EMIRATES VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED ARAB EMIRATES VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED ARAB EMIRATES VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED ARAB EMIRATES VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED ARAB EMIRATES VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 240. UNITED KINGDOM VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 241. UNITED KINGDOM VACCINES MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. UNITED KINGDOM VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 243. UNITED KINGDOM VACCINES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 244. UNITED KINGDOM VACCINES MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 245. VACCINES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 246. VACCINES MARKET, FPNV POSITIONING MATRIX, 2023
目次
Product Code: MRR-434CCDA0513E

The Vaccines Market was valued at USD 68.92 billion in 2023, expected to reach USD 74.16 billion in 2024, and is projected to grow at a CAGR of 7.70%, to USD 115.89 billion by 2030.

Vaccines are biological preparations that provide immunity against specific diseases and are critical in preventive healthcare. The vaccine market encompasses a broad spectrum including prophylactic vaccines for disease prevention and therapeutic vaccines for disease treatment. The necessity of vaccines has been underscored by global health challenges such as the COVID-19 pandemic, increasing the demand for novel vaccine technologies like mRNA vaccines. Applications extend beyond infectious diseases to areas such as cancer, allergies, and autoimmune disorders, while end-use sectors include hospitals, clinics, and research institutes. A significant growth factor is the increased awareness and investments in immunization programs worldwide, further propelled by government and non-governmental organizations. Technological advancements, coupled with expanding research and development funding, present lucrative opportunities for stakeholders to innovate in vaccine delivery mechanisms and stability. However, challenges such as stringent regulatory policies, high R&D costs, and vaccine hesitancy might impede market growth. Moreover, supply chain disruptions and inequitable access in developing countries represent substantial limitations. Promising areas for innovation and research include personalized vaccines, adjuvant technology, and needle-free delivery systems, which could enhance effectiveness and patient compliance. Insights indicate that collaboration between pharmaceutical companies, tech firms, and public health organizations can accelerate breakthroughs. Exploring digital health solutions for enhancing vaccine distribution efficiency and outcome tracking presents untapped potential. Despite the competitive landscape, the market's inherent expansion is nurtured by evolving therapeutic needs and the imperative for global public health security. Overall, the vaccine market holds promise for continuous growth, contingent upon addressing challenges of accessibility and affordability, while leveraging technological innovations to tap into emerging opportunities like personalized immunotherapy and blockchain for supply chain transparency.

KEY MARKET STATISTICS
Base Year [2023] USD 68.92 billion
Estimated Year [2024] USD 74.16 billion
Forecast Year [2030] USD 115.89 billion
CAGR (%) 7.70%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Vaccines Market

The Vaccines Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of new infectious diseases and increase in awareness about the benefits of vaccination
    • Increased government funding encouraging vaccine development
  • Market Restraints
    • High development costs and Issues over product recalls
  • Market Opportunities
    • Surge in investments by biotech companies for innovative vaccine development
    • Emerging collaborations between public and private sectors improve vaccine distribution
  • Market Challenges
    • Lengthy vaccine approval processes and associated side impacts of vaccines

Porter's Five Forces: A Strategic Tool for Navigating the Vaccines Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Vaccines Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Vaccines Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Vaccines Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Vaccines Market

A detailed market share analysis in the Vaccines Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Vaccines Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Vaccines Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Vaccines Market

A strategic analysis of the Vaccines Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Vaccines Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Astellas Pharma Inc., AstraZeneca PLC, Bavarian Nordic A/S, Bharat Biotech Ltd., Biological E. Limited, BioNTech SE, Blue Lake Biotechnology, Capricor Therapeutics, Inc., Chongqing Zhifei Biological Products Co., Ltd., CSL Limited, CureVac N.V., Daiichi Sankyo Company, Limited., Emergent BioSolutions Inc., Gennova Biopharmaceuticals Limited, GlaxoSmithKline PLC, Haffkine Bio-Pharmaceutical Corporation Ltd, Incepta Pharmaceuticals Ltd., Inovio Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Moderna, Inc., Novavax, Inc., Pfizer Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, VBI Vaccines Inc., Versatope Therapeutics, and Zydus Lifesciences Limited.

Market Segmentation & Coverage

This research report categorizes the Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Monovalent Vaccine and Multivalent Vaccine.
  • Based on Technology Type, market is studied across Inactivated Vaccines, Live-Attenuated Vaccines, Messenger RNA (mRNA) Vaccines, Subunit, Recombinant, Polysaccharide, & Conjugate Vaccines, Toxoid Vaccines, and Viral Vector Vaccines.
  • Based on Route of administration, market is studied across Intramuscular & Subcutaneous and Oral.
  • Based on Indication, market is studied across Haemophilus Influenzae Type b, Hepatitis A & Hepatitis B, Human Papillomavirus, Measles, Mumps, & Rubella, Meningococcal Disease, Pneumococcal Disease, Polio, Rabies, Rotavirus, Shingles/Herpes Zoster, Tetanus, Diphtheria, & Pertussis, and Varicella.
  • Based on Age Group, market is studied across Adults and Pediatric.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of new infectious diseases and increase in awareness about the benefits of vaccination
      • 5.1.1.2. Increased government funding encouraging vaccine development
    • 5.1.2. Restraints
      • 5.1.2.1. High development costs and Issues over product recalls
    • 5.1.3. Opportunities
      • 5.1.3.1. Surge in investments by biotech companies for innovative vaccine development
      • 5.1.3.2. Emerging collaborations between public and private sectors improve vaccine distribution
    • 5.1.4. Challenges
      • 5.1.4.1. Lengthy vaccine approval processes and associated side impacts of vaccines
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Critical need for Multivalent vaccines in case of exposure to various strains
    • 5.2.2. Technology Type: Growing significance of mRNA vaccines due to their rapid development and high efficacy
    • 5.2.3. Route of Administration: High preferences for intramuscular (IM) and subcutaneous (SC) routes owing to their strong immune response
    • 5.2.4. Indication: Widespread adoption of influenza vaccines for preventing seasonal flu outbreaks
    • 5.2.5. Age Group: Need for effective vaccination for the elderly and individuals with chronic health conditions
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Vaccines Market, by Type

  • 6.1. Introduction
  • 6.2. Monovalent Vaccine
  • 6.3. Multivalent Vaccine

7. Vaccines Market, by Technology Type

  • 7.1. Introduction
  • 7.2. Inactivated Vaccines
  • 7.3. Live-Attenuated Vaccines
  • 7.4. Messenger RNA (mRNA) Vaccines
  • 7.5. Subunit, Recombinant, Polysaccharide, & Conjugate Vaccines
  • 7.6. Toxoid Vaccines
  • 7.7. Viral Vector Vaccines

8. Vaccines Market, by Route of administration

  • 8.1. Introduction
  • 8.2. Intramuscular & Subcutaneous
  • 8.3. Oral

9. Vaccines Market, by Indication

  • 9.1. Introduction
  • 9.2. Haemophilus Influenzae Type b
  • 9.3. Hepatitis A & Hepatitis B
  • 9.4. Human Papillomavirus
  • 9.5. Measles, Mumps, & Rubella
  • 9.6. Meningococcal Disease
  • 9.7. Pneumococcal Disease
  • 9.8. Polio
  • 9.9. Rabies
  • 9.10. Rotavirus
  • 9.11. Shingles/Herpes Zoster
  • 9.12. Tetanus, Diphtheria, & Pertussis
  • 9.13. Varicella

10. Vaccines Market, by Age Group

  • 10.1. Introduction
  • 10.2. Adults
  • 10.3. Pediatric

11. Americas Vaccines Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Vaccines Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Vaccines Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Mankind Pharma to Acquire Bharat Serums and Vaccines in USD 2 Billion Deal, Expanding Vaccine Production Capabilities
    • 14.3.2. Sanofi and Novavax Partner to Co-Commercialize New COVID-19 Vaccine and Develop Flu-COVID Combo Shot
    • 14.3.3. CureVac and MD Anderson Team Up to Develop mRNA-Based Cancer Vaccines, Paving the Way for Advanced Cancer Treatments
    • 14.3.4. Bharat Biotech and Bilthoven Biologicals Unite to Boost Global Polio Eradication Efforts with Enhanced OPV Production
    • 14.3.5. Takeda Forms Partnership to Boost Global Access to Dengue Vaccine, Targeting Hard-Hit Regions
    • 14.3.6. AstraZeneca Bolsters Vaccine Capabilities by Acquiring Biotechnology Firm Icosavax
    • 14.3.7. Serum Institute of India Partners with CEPI to Boost Global Vaccine Accessibility During Epidemics
    • 14.3.8. GSK Partners with Zhifei to Exclusively Distribute Shingles Vaccine Shingrix in China, Aiming to Enhance Public Health and Vaccine Access
    • 14.3.9. Janssen and Sanofi Join Forces to Develop Vaccine Program to Address Unmet Medical Needs
    • 14.3.10. Global Initiative Boosts Pandemic Preparedness with Funding for Gennova's Self-Amplifying mRNA Vaccine against Disease X
    • 14.3.11. Bavarian Nordic Launches Mpox Vaccine in the U.S., Boosting Preventive Healthcare and Market Innovation
  • 14.4. Strategy Analysis & Recommendation
    • 14.4.1. AstraZeneca PLC
    • 14.4.2. Pfizer Inc.
    • 14.4.3. GlaxoSmithKline PLC
    • 14.4.4. Merck & Co., Inc.
    • 14.4.5. Sanofi S.A.

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Astellas Pharma Inc.
  • 3. AstraZeneca PLC
  • 4. Bavarian Nordic A/S
  • 5. Bharat Biotech Ltd.
  • 6. Biological E. Limited
  • 7. BioNTech SE
  • 8. Blue Lake Biotechnology
  • 9. Capricor Therapeutics, Inc.
  • 10. Chongqing Zhifei Biological Products Co., Ltd.
  • 11. CSL Limited
  • 12. CureVac N.V.
  • 13. Daiichi Sankyo Company, Limited.
  • 14. Emergent BioSolutions Inc.
  • 15. Gennova Biopharmaceuticals Limited
  • 16. GlaxoSmithKline PLC
  • 17. Haffkine Bio-Pharmaceutical Corporation Ltd
  • 18. Incepta Pharmaceuticals Ltd.
  • 19. Inovio Pharmaceuticals, Inc.
  • 20. Johnson & Johnson Services, Inc.
  • 21. Merck & Co., Inc.
  • 22. Moderna, Inc.
  • 23. Novavax, Inc.
  • 24. Pfizer Inc.
  • 25. Sanofi S.A.
  • 26. Serum Institute of India Pvt. Ltd.
  • 27. Sinovac Biotech Ltd.
  • 28. Takeda Pharmaceutical Company Limited
  • 29. VBI Vaccines Inc.
  • 30. Versatope Therapeutics
  • 31. Zydus Lifesciences Limited